RxDoctor Payments DataLook up a doctor →

Aaron Farberg, MD

MOHS-Micrographic Surgery · Rockwall, TXNPI 1134480239

Payments from drug & device makers

$1,866,426in general payments, 2019–2025

Across 1,853 payments — averaging $1007.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$239K
  • Regeneron Healthcare Solutions, Inc.$186K
  • Johnson & Johnson$167K
  • Pfizer$164K
  • Incyte Corporation$142K
  • Galderma Laboratories, L.p.$139K
  • plus $829K from 40 others
$1,261in research payments, 2019–2025

Across 2 payments — averaging $630.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$1K
  • Regeneron$31

What the payments were for

  • Consulting fees$451,38729%
  • Speaking & faculty fees$947,73161%
  • Travel & lodging$102,1767%
  • Food & beverage$39,9023%
  • Education$4,9810%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,866,426 in reported general payments places this provider in the 95th percentile of 109 mohs-micrographic surgery providers in Texas.

See all mohs-micrographic surgery providers in Texas

Medicare billing

Part B allowed, 2024
$1,793,284
Medicare patients
353
Services billed
10,167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Doxycycline Hyclate80$1,015
Mupirocin67$510
Cephalexin47$370
Clobetasol Propionate13$330
Ketoconazole11$215
Triamcinolone Acetonide13$145
Tramadol Hcl11$31

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in Rockwall

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →